British Journal of Clinical Pharmacology

© The British Pharmacological Society

Cover image for Vol. 75 Issue 5

May 2013

Volume 75, Issue 5

Pages i–ii, 1175–1379

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. You have free access to this content
      Issue Information (pages i–ii)

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04432.x

  2. Reviews

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Applied clinical pharmacology and public health in rural Asia – preventing deaths from organophosphorus pesticide and yellow oleander poisoning (pages 1175–1188)

      Michael Eddleston

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04449.x

    2. Neuropeptides and diabetic retinopathy (pages 1189–1201)

      Robert Gábriel

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12003

    3. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis (pages 1202–1212)

      Li-jun Hu, Yun-qing Chen, Song-bai Deng, Jian-lin Du and Qiang She

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12012

  3. Appreciation

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. You have free access to this content
      Sir David Jack: an extraordinary drug discoverer and developer (pages 1213–1218)

      Clive Page and Patrick Humphrey

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04467.x

  4. Commentary

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Clinical pharmacology in health care, teaching and research (pages 1219–1220)

      Michael D. Rawlins

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12074

  5. Translational research

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier® insulin (pages 1221–1230)

      André M. M. Miltenburg, Marita Prohn, Jacqueline H. M. van Kuijk, Renger G. Tiessen, Martin de Kort and Rob J. W. Berg

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04460.x

    2. You have full text access to this OnlineOpen article
      A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease (pages 1231–1239)

      Donald E. Moss, Ruggero G. Fariello, Jörg Sahlmann, Isabel Sumaya, Federica Pericle and Enrico Braglia

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12018

  6. Pharmacodynamics

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers (pages 1240–1254)

      S. Aubrey Stoch, Stefan Zajic, Julie A. Stone, Deborah L. Miller, Lucas van Bortel, Kenneth C. Lasseter, Barnali Pramanik, Caroline Cilissen, Qi Liu, Lida Liu, Boyd B. Scott, Deborah Panebianco, Yu Ding, Keith Gottesdiener and John A. Wagner

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04471.x

    2. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis (pages 1255–1264)

      Marc Trellu, Jean-Baptiste Fau, Pierre Cortez, Sue Cheng, Isabelle Paty, Emmanuelle Boëlle, François Donat and Ger-Jan Sanderink

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12009

  7. Pharmacokinetics

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Prophylactic ranitidine treatment in critically ill children – a population pharmacokinetic study (pages 1265–1276)

      Ahmed F. Hawwa, Paul M. Westwood, Paul S. Collier, Jeffrey S. Millership, Shirish Yakkundi, Gillian Thurley, Mike D. Shields, Anthony J. Nunn, Henry L. Halliday and James C. McElnay

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04473.x

    2. Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation (pages 1277–1288)

      Flora T. Musuamba, Michel Mourad, Vincent Haufroid, Martine De Meyer, Arnaud Capron, Isabelle K. Delattre, Roger K. Verbeeck and Pierre Wallemacq

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12007

    3. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study (pages 1289–1298)

      Bart van Hartingsveldt, Ivo P. Nnane, Esther Bouman-Thio, Matthew J. Loza, Alexa Piantone, Hugh M. Davis and Kevin J. Petty

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04477.x

    4. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers (pages 1299–1311)

      Ahmed A. Othman, George Haig, Hana Florian, Charles Locke, Jun Zhang and Sandeep Dutta

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04472.x

  8. Pharmacokinetic dynamic relationships

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol (pages 1312–1320)

      Frantz Foissac, Jean-Marc Tréluyer, Jean-Claude Souberbielle, Hafeda Rostane, Saïk Urien and Jean-Paul Viard

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12006

  9. Drug interactions

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study (pages 1321–1327)

      Karin P. W. Schoenmakers, Tom B. Vree, Nigel T. M. Jack, Bart van den Bemt, Jacques van Limbeek and Rudolf Stienstra

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04470.x

    2. Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers (pages 1328–1339)

      Erik T. te Beek, Justin L. Hay, Jonathan N. Bullman, Clare Burgess, Kimberly J. Nahon, Erica S. Klaassen, Frank A. Gray and Joop M. A. van Gerven

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12004

  10. Pharmacogenetics

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Analgesia and central side-effects: two separate dimensions of morphine response (pages 1340–1350)

      Joanne M. Droney, Sophy K. Gretton, Hiroe Sato, Joy R. Ross, Ruth Branford, Kenneth I. Welsh, William Cookson and Julia Riley

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12008

  11. Drug safety

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Dronedarone-associated acute renal failure: evidence coming from the Italian spontaneous ADR reporting database (pages 1351–1355)

      Chiara Biagi, Mauro Venegoni, Mauro Melis, Elena Buccellato, Nicola Montanaro and Domenico Motola

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12005

  12. Pharmacoepidemiology

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study (pages 1356–1364)

      Anton Pottegård, Søren Friis, Morten Andersen and Jesper Hallas

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12001

  13. Letters to the editors

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. You have full text access to this OnlineOpen article
      Are there any differences in the regulations of personalized medicine among the USA, EU and Japan? (pages 1365–1367)

      Rumiko Shimazawa and Masayuki Ikeda

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04462.x

    2. Response to the comments from Drs Shimazawa and Ikeda (pages 1368–1369)

      Rashmi R. Shah and Devron R. Shah

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04461.x

    3. Authors' response to Marras and Oakes, ‘piecing together the puzzle of progression and mortality in Parkinson's disease’ (pages 1370–1371)

      Nicholas H. G. Holford, Thuy C. Vu and John G. Nutt

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04465.x

    4. Author reply to Holford, Vu and Nutt regarding ‘piecing together the puzzle of progression and mortality in Parkinson's disease’ (page 1372)

      Connie Marras and David Oakes

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04464.x

    5. Antidepressant use and gestational hypertension: does evidence support causality? (pages 1373–1374)

      Luke E. Grzeskowiak, Lars H. Pedersen and Janna L. Morrison

      Article first published online: 8 APR 2013 | DOI: 10.1111/j.1365-2125.2012.04468.x

    6. Antidepressant use and gestational hypertension: does evidence support causality? Reply letter (pages 1375–1376)

      Anick Bérard and Mary A. De Vera

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12020

  14. Book review

    1. Top of page
    2. Issue Information
    3. Reviews
    4. Appreciation
    5. Commentary
    6. Translational research
    7. Pharmacodynamics
    8. Pharmacokinetics
    9. Pharmacokinetic dynamic relationships
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Pharmacoepidemiology
    14. Letters to the editors
    15. Book review
    1. Bad Pharma: how drug companies mislead doctors and harm patients – By Ben Goldacre (pages 1377–1379)

      Humphrey Rang

      Article first published online: 8 APR 2013 | DOI: 10.1111/bcp.12047

SEARCH

SEARCH BY CITATION